Application of sodium fluorescein in sentinel lymph node biopsy in early invasive breast cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036990

Enrollment

Unknown

Registered

2020-08-26

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Group A: ICG combined with methylene blue

Group B:fluorescein combined with methylene blue

Eligibility

Sex/Gender

Female

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Sentinel lymph node biopsy is required for pathologically confirmed breast cancer aged 20-80 years.

Exclusion criteria

Exclusion criteria: 1. Prior history of fluorescein allergy and breast or axillary surgery; 2. Abnormal creatinine level; 3. Abnormal liver function; 4. Preoperative axillary lymph nodes have a high degree of suspicious or histologically confirmed metastases.

Design outcomes

Primary

Measure	Time frame
Detectable rate;Accuracy;Sensitivity;	—

Countries

China

Contacts

Public ContactLiang Li

Zibo Central Hospital

liliangzb@sina.com+86 18653371077

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026